{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015505","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.139583+00:00","generated_at":"2026-06-24T02:36:40.996758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement","bullets":["Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.","Cash, equivalents and marketable securities $292.7M; expects sufficient for two years.","Filed patent infringement suit against Pfizer over Paxlovid; seeks damages, not injunction; patent awarded June 2022.","EDP-235 Phase 1 data positive; Phase 2 study planned Q4 2022; RSV programs include new Phase 2 studies for EDP-938 and EDP-323.","Appointed Scott T. Rottinghaus as SVP and Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015505","json":"https://secwatch.observer/filing/0000950170-22-015505.json","markdown":"https://secwatch.observer/filing/0000950170-22-015505.md","text":"https://secwatch.observer/filing/0000950170-22-015505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/0000950170-22-015505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/enta-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:36:40.996758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}